Status:
COMPLETED
Predictors of Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease Patients
Lead Sponsor:
Seoul National University Bundang Hospital
Conditions:
Erosive Reflux Disease
Non-erosive Reflux Disease
Eligibility:
All Genders
16-85 years
Brief Summary
Proton pump inhibitor (PPI) is widely used in patients with gastroesophageal reflux disease (GERD), however, some patients fail to respond to PPI therapy. Recent reporters suggest that depressive diso...
Eligibility Criteria
Inclusion
- Adult Subjects (From 16 to 85 years old)
- The participants with GERD symptoms were treated a PPI therapy.
- The participants completed a questionnaire. The questionnaire consisted of demographic data, GERD symptoms, GERD impact scale (GIS), Epworth sleepiness scale (ESS), Pittsburgh sleep quality index (PSQI), Hospital anxiety and depression scale (HADS), and WHO quality of life scale abbreviated version (WHOQOL-BREF).
Exclusion
- Patients with a history of gastrointestinal surgery, Barrett's esophagus, esophageal motility disorder, peptic ulcer or gastroduodenal cancer and systemic disease requiring chronic medication (except for hypertension and diabetes mellitus) were excluded.
- Patients who took the PPI therapy less than 4 weeks were excluded.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
197 Patients enrolled
Trial Details
Trial ID
NCT01797939
Start Date
July 1 2008
End Date
December 1 2012
Last Update
February 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 463-707